Literature DB >> 3493912

Opposite effects of a D1 and a D2 agonist on oral movements in rats.

P Johansson, E Levin, L Gunne, G Ellison.   

Abstract

Oral movements in rats administered one of three doses of either a D1 agonist (SK&F 38393) or a D2 agonist (LY171555) were observed via closed-circuit television and simultaneously recorded using a computerized video analysis system which measured the distance between two fluorescent dots painted above and below the rat's mouth. The D1 agonist SK&F 38393 induced a dose-dependent increase in tremorous oral movements, tongue protrusions, and, at the highest dose, increased repetitive chewing movements. Conversely, the D2 agonist LY171555 produced an inhibition or oral activity at all dose levels. At the lowest dose tested this appeared to reflect a non-specific decrease in activity, for there was an inhibition of all categories of behavior measured, as well as of all amplitudes of computer-scored movements and slow, sluggish movements were recorded. But higher doses of LY171555 induced hyperactivity and stereotyped, repetitive head movements whereas chewing movements, tremorous oral movements, and tongue protrusions were still decreased. D1 and D2 dopamine receptors appear to have opposite effects on oral movements.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3493912     DOI: 10.1016/0014-2999(87)90134-8

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  27 in total

1.  Psychopharmacological responsiveness to the dopamine agonist quinpirole in normal weanlings and in weanling offspring exposed gestationally to cocaine.

Authors:  C A Moody; N A Frambes; L P Spear
Journal:  Psychopharmacology (Berl)       Date:  1992       Impact factor: 4.530

2.  Ontogenetic differences in the psychopharmacological responses to separate and combined stimulation of D1 and D2 dopamine receptors during the neonatal to weanling age period.

Authors:  C A Moody; L P Spear
Journal:  Psychopharmacology (Berl)       Date:  1992       Impact factor: 4.530

3.  Dopaminergic control of locomotion, mouthing, snout contact, and grooming: opposing roles of D1 and D2 receptors.

Authors:  D Eilam; H Talangbayan; G Canaran; H Szechtman
Journal:  Psychopharmacology (Berl)       Date:  1992       Impact factor: 4.530

4.  Effect of chronic D-1 and/or D-2 dopamine antagonist treatment on SKF 38393-induced non-stereotyped grooming.

Authors:  S A Parashos; C Marin; P Barone; V Kapitzoglou-Logothetis; T N Chase
Journal:  Psychopharmacology (Berl)       Date:  1990       Impact factor: 4.530

5.  Drug-induced oral dyskinesias in rats after traditional and new neuroleptics.

Authors:  T Kakigi; X M Gao; C A Tamminga
Journal:  J Neural Transm Gen Sect       Date:  1995

6.  Chronic neuroleptics alter the effects of the D1 agonist SK&F 38393 and the D2 agonist LY171555 on oral movements in rats.

Authors:  G Ellison; P Johansson; E Levin; R See; L Gunne
Journal:  Psychopharmacology (Berl)       Date:  1988       Impact factor: 4.530

7.  Electromyographical differentiation of the components of perioral movements induced by SKF 38393 and physostigmine in the rat.

Authors:  P Collins; C L Broekkamp; P Jenner; C D Marsden
Journal:  Psychopharmacology (Berl)       Date:  1993       Impact factor: 4.530

8.  Biphasic locomotor effects of the dopamine D1 agonist SKF 38393 and their attenuation in non-habituated mice.

Authors:  E Tirelli; P Terry
Journal:  Psychopharmacology (Berl)       Date:  1993       Impact factor: 4.530

9.  Effects of ceruletide on perioral movements and the dopamine receptor-adenylate cyclase system in rats chronically treated with fluphenazine.

Authors:  T Ashizawa; T Saito; N Takahata
Journal:  Psychopharmacology (Berl)       Date:  1996-06       Impact factor: 4.530

10.  Effects of acute dopamine depletion on responsiveness to D1 and D2 receptor agonists in infant and weanling rat pups.

Authors:  C A Moody; L P Spear
Journal:  Psychopharmacology (Berl)       Date:  1992       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.